Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.00
Bid: 1,603.50
Ask: 1,604.00
Change: -162.50 (-9.20%)
Spread: 0.50 (0.031%)
Open: 1,616.50
High: 1,620.00
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: FTSE 100 Closes Up For Sixth Day, Third Week In A Row

Fri, 21st Feb 2014 17:12

LONDON (Alliance News) - The FTSE 100 closed higher for the sixth consecutive day Friday, closing less than 100 points short of its 2014 opening level as investors shrugged off a host of weaker-than-expected UK and US data releases to ensure the global equity rally continues.

The FTSE 100 closed up 0.4% at 6,838.06, which means the blue-chip index has now ended the week higher than it started it for the third week in a row. The FTSE 250 closed up 0.6% at 16,460.88, while the AIM All-Share index snapped an 11-day winning streak closing down 0.2% at 881.6.

Positive sentiment was evident across the world Friday, with the CAC 40 in Paris closing up 0.6%, the DAX 30 in Frankfurt closing up 0.5%, and Asian equities closing broadly higher earlier in the day, with the excepted of the Shanghai Composite index.

In the US, at the close of the London equity market, the DJIA and S&P 500 are both up 0.3%, with the NASDAQ Composite up 0.4%.

British retail sales declined at the sharpest pace since 2012 in January, as food sales weakened noticeably after Christmas, data from the Office of National Statistics revealed. Retail sales volume, including automotive fuel, fell 1.5% month-on-month in January, which was the first decline in three months and the biggest since April 2012. Economists had expected the sales to fall by 1%, following a 2.5% rise in December.

Despite this, the latest decline has to be viewed in the context of the surge in sales in December and the very wet weather experienced in January, which will have deterred consumers from venturing to the shops, said James Knightley, economist at ING Bank NV.

Forex.com's research director Kathleen Brooks added: "The good news for British retailers is that despite this month-on-month fall, the quantity bought still remains strong, and the underlying trend in the data, suggested by the three month-on-three month growth rate for retail sales, actually increased by 1.1% in January, thus confirming strong momentum in consumption."

Nevertheless, food store sales slipped 3.4% in January, with non-food store sales gaining 0.4%.

In a separate report, released at the same time, UK public sector net borrowing declined by GBP6.43 billion in January, down from a revised GBP9.03 billion rise in December. Consensus expectations were for a fall to GBP9.00 billion.

The pound, which had been sold in the run-up to the data, jumped to regain its losses in the aftermath, before slipping again late in the day. At the close of the UK equity markets, sterling trades at EUR1.2123 and CHF1.4798.

The currency pushed even higher against the dollar later in the trading session as home sales data from the world's largest economy disappointed.

The National Association of Realtors revealed that sales of previously owned homes fell 5.1% in January to an annual rate of 4.62 million. Economists had expected the rate of sales to come in at 4.68 million, down 4.3%.

The data caused the dollar to drop against its major rivals, before it regained some of its strength later in the session. At the London stock market close, the pound trades at USD1.6641, the euro at USD1.3723, and the Swiss franc at USD1.1247.

At the individual stock level, Royal Bank of Scotland Group, closing up 1.2%, was among the leading gainers in the FTSE 100. The Financial Times quoted people familiar with the banks plans saying it is preparing a dramatic retrenchment that would see it become a much smaller UK retail and commercial bank. The restructuring will form part of a series of cost-cutting measures and disposals led by new Chief Executive Ross McEwan, and is expected to see staff numbers slashed by at least 30,000 in the coming years, the paper said.

Following the report, Shore Capital reiterated its Buy recommendation, saying that the move is likely to result in a, "smaller but more efficient, higher return and less risky bank."

The company was outperformed by Vodafone, however, which closed up 3%. US blue-chip Verizon Communications said Friday that it has completed its acquisition of Vodafone's 45% indirect interest in Verizon Wireless in a transaction valued at about USD130 billion. As previously announced, Verizon issued about 1.27 billion common shares to shareholders of Vodafone as the stock portion of the consideration for Vodafone's 45% indirect interest in Verizon Wireless.

GlaxoSmithKline, closing up 0.9%, was also amongst the leading gainers after it said Incruse, a treatment for chronic obstructive pulmonary disease, had been recommended for marketing authorisation by the European Medicines Agency's committee for Medical Products for Human Use, a key step in getting approval for the drug.

In the FTSE 250, IP Group ended the day as the index's leading gainer, up 3.7%. The group's share price jumped after it said that its portfolio company, Xeros Ltd, intends to float on AIM to raise funds to bring its patented polymer bead cleaning system to the laundry market.

Millennium & Copthorne Hotels, closing up 3.1%, was another of the index's biggest winners after it reported higher revenues and profits for 2013, even though the improvements were due to a one-off profit boost from its Glyndebourne property development in Singapore at the end of the fourth quarter, and it cautioned that its room refurbishment programme would continue to weigh on its results this year.

The group's revenue increased to the record level of GBP1.04 billion in 2013, due to a GBP273.7 million revenue boost from the Glyndebourne development in Singapore, with pretax profit rising to GBP263.6 million in the year, up from GBP171.3 million in 2012.

Meanwhile, in the AIM All-Share index, The Real Good Food Company closed down 26% after it said it is in a pricing dispute with Associated British Foods' British Sugar unit, a major supplier to Real Good Food's Napier Brown non-refining sugar distribution business.

The group has complained to the Office of Fair Trading that British Sugar is charging too much and abusing its dominant position in the UK sugar market. It said the dispute is unlikely to be quickly resolved and will weigh on its results this year and next.

In the data calendar Monday, German IFO business climate data are released at 0900 GMT, ahead of EU consumer price inflation data for January at 1000 GMT.

In the US, the Chicago Federal Reserve releases its national activity index at 1330 GMT. US Markit services PMI is released at 1358 GMT, with the Dallas Fed publishing the Texas manufacturing outlook survey at 1530 GMT.

In the corporate calendar, FTSE 100-constituent Bunzl is joined by FTSE 250-listed Bovis Homes and Hiscox in releasing full-year results for 2013 ahead of the London stock market open. The blue-chip index's largest company by market capitalization, HSBC Holdings, releases its full-year results at 0815 GMT.

Meanwhile, Associated British Foods releases a trading statement.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
Today 09:08

TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac

(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.

Read more
Today 08:37

LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs

(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.

Read more
Today 08:00

LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim

(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.

Read more
Today 07:30

GSK to appeal Delaware ruling on jury trials in Zantac cancer cases

(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
24 May 2024 15:19

London close: Stocks mixed after disappointing retail sales data

(Sharecast News) - London stocks closed with mixed results on Friday, influenced by earlier declines in the US and Asian markets, as investors reacted to a larger-than-expected drop in UK retail sales.

Read more
24 May 2024 08:55

LONDON MARKET OPEN: FTSE 100 falls; retail sales plunge in April

(Alliance News) - Stock prices in London opened lower on Friday, with sentiment hurt across the globe.

Read more
24 May 2024 08:36

TOP NEWS: GSK celebrates Illinois jury verdict in Valadez case

(Alliance News) - GSK PLC on Friday welcomed the jury verdict in the Valadez case in Illinois state court, which found in GSK's favour in the first Zantac case to go to trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.